Advertisement
Singapore markets closed
  • Straits Times Index

    3,301.78
    +4.23 (+0.13%)
     
  • S&P 500

    5,473.23
    +41.63 (+0.77%)
     
  • Dow

    38,778.10
    +188.94 (+0.49%)
     
  • Nasdaq

    17,857.02
    +168.14 (+0.95%)
     
  • Bitcoin USD

    65,097.12
    -562.05 (-0.86%)
     
  • CMC Crypto 200

    1,356.14
    -33.26 (-2.39%)
     
  • FTSE 100

    8,178.89
    +36.74 (+0.45%)
     
  • Gold

    2,328.90
    -0.10 (-0.00%)
     
  • Crude Oil

    80.36
    +0.03 (+0.04%)
     
  • 10-Yr Bond

    4.2790
    0.0000 (0.00%)
     
  • Nikkei

    38,482.11
    +379.67 (+1.00%)
     
  • Hang Seng

    17,915.55
    -20.57 (-0.11%)
     
  • FTSE Bursa Malaysia

    1,606.13
    -1.19 (-0.07%)
     
  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     
  • PSE Index

    6,368.80
    -14.90 (-0.23%)
     

Amneal to Participate at Upcoming Investor Conference

BRIDGEWATER, N.J., May 22, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.

Chirag will present at 1:30 PM EST. A live webcast of the presentation will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522763089/en/

Contacts

Investor Contact:
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com